However, these positive outcomes of immune checkpoint blockade therapy in murine GBM models were not translated into clinical trials; no superior progression-free survival was observed in glioma patients treated with anti-PD-1 monoclonal antibody 2. This evidence concerns the gene PDCD1 and glioma.